All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | Efficacy and safety of midostaurin plus intensive chemotherapy in newly diagnosed patients with FLT3-mutated AML
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
FMS-like tyrosine kinase 3 (FLT3) is a commonly occurring gene mutation in approximately 30% of patients with acute myeloid leukemia (AML). Midostaurin is a multikinase, first-generation, type 2 inhibitor that directly inhibits FLT3 signaling and induces apoptosis in FLT3-mutated leukemic cells. The pivotal RATIFY trial, previously reported by the AML Hub, demonstrated that midostaurin significantly reduced mortality in adult patients aged <60 years with newly diagnosed FLT3-mutated AML.1
The AML Hub is pleased to present a visual abstract summarizing the efficacy and safety outcomes from a phase IIIb trial (NCT03379727) of midostaurin plus idarubicin or daunorubicin in young (≤60 years) and older (≥60 years) patients with newly diagnosed FLT3-mutated AML.1
Your opinion matters
11 votes - 11 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox